# Development of Magnetic Resonance Spectroscopy (MRS) Biomarkers of Tumor Metabolism (MK-0000-145)

> **NCT01138813** · — · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 8 (actual)

## Conditions studied

- Glioma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01138813
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2010-02
- **Final completion:** 2010-02
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2015-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01138813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01138813, "Development of Magnetic Resonance Spectroscopy (MRS) Biomarkers of Tumor Metabolism (MK-0000-145)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01138813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*